ICI Myocarditis: 1% Risk, 50% Fatal – UCSF Expert Insights!

ARTICLE: https://oncologytube.com/immune-check...
Discover the critical risks of immune checkpoint inhibitors myocarditis with UCSF expert Javid Moslehi, MD. Learn why this 1% risk condition can be 50% fatal, the latest on detection, and advanced treatments from an international registry of over 1,250 cases. Explore how combination ICIs spike risks 3-5x, early signs like chest pain and diplopia, and innovative diagnostics like PET tracers. Plus, hear about mouse models and therapies like abatacept and ruxolitinib. Perfect for oncologists and healthcare pros aiming to optimize cancer care while managing cardiac toxicities. Subscribe for more cardio-oncology insights!

TimeStamps:
00:00:00 - Intro: 1% Risk, 50% Fatal Statistic
00:00:13 - Combination ICIs Increase Risk 3-5x
00:00:20 - Meet Javid Moslehi, MD, UCSF
00:00:31 - How ICIs Cause Heart Inflammation
00:00:37 - Side Effects: Myocarditis & More
00:01:06 - Main Cardiac Toxicities
00:01:10 - Severity & Infrequency
00:01:21 - Early Signs & Timing
00:01:28 - Symptoms & Distinguishing Features
00:01:45 - Diagnosis with Troponin & CK
00:02:20 - Mouse Studies for Treatment & Diagnosis
00:03:01 - New Scans & Drugs for Detection
00:03:08 - Challenges & PET Tracer Innovations
00:03:39 - Treatment Protocols: Abatacept & Ruxolitinib

Video interviews to be posted from this event at these websites...
https://oncologytube.com/tag/moasc/
https://moasc.org/
https://anco.org/

About OncologyTube.com:
OncologyTube.com is a free video-sharing platform dedicated to oncology professionals, offering cancer research updates through videos, audio, PowerPoint presentations, and more. Visit OncologyTube.com for a detailed web post on this and many other cancer topics and oncology insights.

Follow OncologyTube:
eNewsletter: https://oncologytube.com/newsletter/
Twitter:   / oncologytube  
LinkedIn:   / oncologytube-com  
Facebook:   / oncologytube  
Instagram:   / oncologytube  
YouTube:    / oncologytube  

Connect with Us:
Share your thoughts in the comments! Join the discussion.